Aileron Therapeutics Inc (NASDAQ:ALRN) Short Interest Update
Aileron Therapeutics Inc (NASDAQ:ALRN) was the recipient of a significant growth in short interest in the month of July. As of July 15th, there was short interest totalling 387,100 shares, a growth of 8.4% from the June 15th total of 357,200 shares. Currently, 4.7% of the company’s shares are short sold. Based on an average daily volume of 241,800 shares, the short-interest ratio is currently 1.6 days.
Shares of NASDAQ ALRN remained flat at $$0.54 during trading hours on Tuesday. The company had a trading volume of 66,764 shares, compared to its average volume of 349,993. The company has a quick ratio of 3.11, a current ratio of 3.11 and a debt-to-equity ratio of 0.38. The company has a 50-day simple moving average of $0.70. Aileron Therapeutics has a 12-month low of $0.44 and a 12-month high of $4.10.
Aileron Therapeutics (NASDAQ:ALRN) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.13). Equities research analysts anticipate that Aileron Therapeutics will post -1.11 earnings per share for the current year.
An institutional investor recently raised its position in Aileron Therapeutics stock. Jennison Associates LLC lifted its position in Aileron Therapeutics Inc (NASDAQ:ALRN) by 649.6% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,040,255 shares of the company’s stock after acquiring an additional 1,768,073 shares during the period. Jennison Associates LLC owned 13.72% of Aileron Therapeutics worth $3,828,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 29.17% of the stock is owned by institutional investors.
Aileron Therapeutics Company Profile
Aileron Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside.
Further Reading: Oversold
Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.